HomeQuestion

How do you differentiate between osseous metastases and Paget's disease on PSMA PET?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

How do you manage PSA progression while a patient is on Xofigo or Pluvicto?

How do you decide between radioligand therapy or cytotoxic chemotherapy in patients with metastatic castration-resistant prostate cancer with prior ARPI exposure who have cancer-related anemia?

Should a patient who requires definitive treatment for prostate cancer as a pre-transplant requirement be strictly required to complete their course prior to transplant/initiation of immunosuppression?

How do you interpret nodes with minimal increased uptake on PSMA PET in prostate cancer?

How does the POSEIDON meta-analysis results influence your decision on which patients should receive hormone therapy with post-operative radiotherapy for recurrent prostate cancer?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.

How do you differentiate between osseous metastases and Paget's disease on PSMA PET? | Mednet